Clifutinib Besylate

DRUG2 trials

Sponsors

Sunshine Lake Pharma Co., Ltd.

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia, Adult

Phase 1

A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)

CompletedNCT04827069

Sunshine Lake Pharma Co., Ltd.Acute Myeloid Leukemia

Start: 2018-05-18End: 2023-08-30Updated: 2024-09-19

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

RecruitingNCT05133882

Sunshine Lake Pharma Co., Ltd.Acute Myeloid Leukemia, Adult

Start: 2022-10-31End: 2028-06-30Target: 133Updated: 2026-05-15

Related Papers

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Blood2023-11-022 citations

P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

HemaSphere2022-06-011 citations